Perimenopause: When the Cardiovascular Changes Actually Begin

Most women expect cardiovascular risk to change at menopause, meaning after the periods stop. The change starts earlier, during perimenopause, the years of fluctuating and ultimately declining hormones leading up to the final period. That timing detail is not academic. It identifies the window where prevention has the most effect, because the changes are caught while they are still small and most responsive to intervention.

The Mechanism

Perimenopause is not a smooth hormonal decline. It is a period of erratic ovarian function: cycles become irregular, estrogen levels fluctuate widely between cycles, and progesterone production falls as ovulation becomes less reliable. This hormonal instability produces direct effects on the vasculature, the liver, and adipose tissue, all of which begin shifting before the final period ever arrives.

The liver’s regulation of lipoprotein production is sensitive to estrogen. As ovarian estrogen output becomes more variable and the average exposure declines, hepatic production of LDL particles increases and LDL receptor activity decreases. The net effect is a rise in circulating LDL cholesterol and, more specifically, a rise in apolipoprotein B (ApoB), the protein carried on every atherogenic lipoprotein particle. ApoB is a more direct measure of the particle burden driving atherosclerosis than LDL cholesterol alone, and it begins to rise during perimenopause, not after.

Vascular function also changes during this period. Estrogen promotes endothelial production of nitric oxide, which maintains arterial elasticity and keeps vascular tone low. As estrogen exposure becomes less consistent, flow-mediated dilation, a measure of endothelial health, declines. The SWAN Heart substudy documented changes in arterial stiffness and endothelial function that began in the perimenopausal years, preceding the metabolic changes by a measurable interval in some participants.

Insulin sensitivity is another early casualty of the transition. The wide estrogen fluctuations of perimenopause impair glucose uptake in skeletal muscle through mechanisms involving estrogen receptor signaling in insulin-sensitive tissues. This decline in insulin sensitivity precedes overt changes in fasting glucose and tends to show up first as postprandial glucose elevation, which standard fasting labs miss. The metabolic consequence is increased hepatic triglyceride production, compounding the lipid shift already underway.

Body composition begins to change as well. The preferential deposition of visceral fat, the metabolically active fat surrounding the intra-abdominal organs, is not a consequence of postmenopause. It begins to accelerate during the perimenopausal years. Lovejoy and colleagues, in controlled studies that separated menopausal status from age, demonstrated that the hormonal transition itself, rather than aging, drove the shift toward central adiposity. Visceral fat secretes inflammatory mediators and contributes to both insulin resistance and dyslipidemia, creating a feed-forward loop that amplifies the lipid changes above.

There is also a cardiac structural dimension to perimenopause that receives less attention. Estrogen receptors are present on cardiac myocytes and on vascular smooth muscle cells throughout the arterial tree. As estrogen signaling decreases during perimenopause, the signaling environment within the myocardium and the coronary vasculature changes. Studies using cardiac MRI in perimenopausal and early postmenopausal women have documented early changes in left ventricular geometry and diastolic function that precede any symptoms and are not captured by standard echocardiographic screening at typical clinical thresholds. The clinical implication is that the cardiovascular changes of perimenopause are not limited to lipids and blood pressure but include early structural and functional shifts in the heart itself.

Autonomic nervous system balance also shifts across the transition. Estrogen modulates the balance between sympathetic and parasympathetic tone. As its levels fluctuate and then decline, heart rate variability, a marker of parasympathetic cardiac control and a predictor of cardiovascular outcomes, decreases. This shift toward higher sympathetic tone contributes to the blood pressure variability seen in perimenopausal women and may help explain why ambulatory blood pressure measurements, which capture the full diurnal pattern including nighttime dipping, sometimes reveal hypertension that resting clinic measurements miss.

Coagulation also shifts during perimenopause in a direction that is modestly prothrombotic. Plasma fibrinogen, factor VII, and plasminogen activator inhibitor-1 levels tend to increase as estrogen support of fibrinolytic pathways declines. While these changes are not of the magnitude seen in conditions like antiphospholipid antibody syndrome, they contribute incrementally to the overall cardiovascular risk profile of the transition, particularly in combination with the lipid and blood pressure changes occurring simultaneously. The convergence of multiple modest changes during a compressed time window is what makes the perimenopausal transition a period of meaningfully accelerating vascular risk, even when no single measure has crossed a clinical threshold.

What the Evidence Shows

The SWAN study (Study of Women’s Health Across the Nation) is the foundational dataset for understanding perimenopausal cardiovascular changes. SWAN followed a diverse cohort of women through the menopausal transition with serial measurements, allowing researchers to map the timing of changes relative to the final menstrual period rather than to age alone.

Matthews and colleagues, publishing from SWAN, showed that LDL cholesterol rose most steeply in the two years immediately flanking the final menstrual period, with a mean increase in the range of 10 to 14 mg/dL concentrated in that narrow window. The rise began in late perimenopause, not after menopause was established. The same analyses documented that ApoB rose in parallel, confirming that the atherogenic particle burden was increasing, not just the cholesterol measurement.

El Khoudary and colleagues, also publishing from SWAN, extended this picture with vascular imaging. Women with greater symptom burden during perimenopause, including more frequent or severe vasomotor symptoms, had higher coronary artery calcification scores in subsequent imaging. The association held after adjusting for traditional risk factors, which suggests that the vasomotor symptoms and the vascular stress of the transition share a common underlying biology. A woman whose hot flashes are severe during perimenopause may be experiencing a signal about her vascular biology, not just about her thermoregulatory system.

The ARIC study (Atherosclerosis Risk in Communities) contributed long-term follow-up data showing that women who experienced early menopause, defined as menopause before age 45, carried materially higher cardiovascular risk over subsequent decades. While ARIC followed postmenopausal women rather than tracking the transition itself, its findings reinforce the principle that the hormonal biology of the menopausal transition carries independent cardiovascular weight beyond standard risk factor accumulation.

Vlachopoulos and colleagues published data from European cohorts on arterial stiffness across the menopausal transition, confirming that pulse wave velocity, a direct measure of arterial stiffness and a predictor of cardiovascular events, increased during the perimenopausal transition and continued rising after menopause. The perimenopausal increase was not simply explained by blood pressure change alone.

On the metabolic side, the Women’s Health Initiative observational cohort documented that women entering the study in the early postmenopausal years, within a few years of their final period, had lipid and metabolic profiles that were already substantially shifted from premenopausal values, consistent with the SWAN timeline showing that most of the movement happened during perimenopause itself.

The Nurses’ Health Study provided evidence on the cardiovascular consequences of early natural menopause, defined as menopause before age 45, which can be conceptualized as accelerated perimenopause. Colditz and colleagues reported that women who experienced early natural menopause had approximately 1.5 to 2 times the coronary risk of women who reached menopause at a typical age, with the risk compounding the longer they had been postmenopausal. The mechanism running through this association is the same one visible in perimenopause more generally: the earlier the hormonal transition begins in earnest, the more cumulative vascular exposure women accumulate in subsequent years.

One practical implication of the perimenopausal timing of cardiovascular changes is that standard screening intervals, which often space lipid and metabolic testing years apart in middle-aged adults without prior cardiovascular disease, may be insufficient to capture rapidly moving targets during the transition. A woman who had a normal lipid panel at age 44 and is re-screened at age 48 after four years of perimenopausal fluctuation may have a profile that is materially different from what she expects. The SWAN data, which followed women with more frequent measurement intervals specifically to characterize the trajectory, demonstrated precisely this: the LDL rise was concentrated in a narrow window that annual or biannual screening would capture well but four-year intervals would miss entirely.

Arterial Stiffness: The Vascular Change That Precedes the Numbers

Among the cardiovascular changes that accumulate during perimenopause, arterial stiffening may be the earliest and least visible. It predates rises in LDL, precedes blood pressure elevation on standard testing, and accumulates silently in the vessel wall while every other clinical marker appears within range. It is also measurable with techniques that are increasingly available in vascular imaging suites and research-adjacent clinical settings.

Arterial stiffness refers to the reduced capacity of large elastic arteries — the aorta and the major conduit vessels — to expand during systole and recoil during diastole. In a young, estrogen-replete woman, the arterial wall contains abundant elastin and responds to the pulsatile pressure of each heartbeat in a way that buffers the pulse wave before it reaches the peripheral microvasculature. As estrogen declines during perimenopause, structural changes in the arterial wall reduce this elasticity: collagen cross-linking increases, elastin degrades, and nitric oxide-mediated vasorelaxation decreases. The result is a stiffer vessel that transmits pulse pressure more directly to the microcirculation, particularly in the kidneys and the brain, where it causes target organ damage at accelerated rates.

Pulse wave velocity — the speed at which a pressure wave travels through the arterial tree — is the most widely validated measure of arterial stiffness. Higher velocity indicates a stiffer, more rigid vessel. Vlachopoulos and colleagues, pooling data from European cohort studies, demonstrated that pulse wave velocity increases during the perimenopausal transition independently of blood pressure change. The increase was detectable in women in late perimenopause and accelerated further in early postmenopause, consistent with a biological driver related to the hormonal transition rather than age alone.

The SWAN Heart Study extended this picture to the coronary vasculature. El Khoudary and colleagues tracked aortic calcification using CT imaging across the perimenopausal transition and found that the rate of calcification increased during late perimenopause and early postmenopause, with women who had more severe vasomotor symptoms showing higher rates of calcification accumulation. Coronary calcification is a direct marker of atherosclerotic burden; its acceleration during the transition reinforces that the vascular biology of perimenopause is not benign even when lab values appear reassuringly normal.

Flow-mediated dilation, a brachial artery ultrasound measure of endothelial-dependent vasodilation, also declines during perimenopause. Several European cohorts, including the Malmö Preventive Project, have shown that flow-mediated dilation falls measurably during the perimenopausal years, parallel to the decline in estrogen bioavailability, and remains suppressed in early postmenopause.

The clinical implication of these vascular findings is that the cardiovascular changes of perimenopause are not limited to the measurable risk factors that appear on a standard lab panel. They include structural and functional changes in the arterial wall that accumulate before LDL or blood pressure crosses a threshold, and that contribute to long-term cardiovascular risk independently of those traditional markers. Measurement during the transition catches the trajectory at its most modifiable point.

What to Do This Week

1. Establish your baseline numbers now, during perimenopause, rather than waiting for menopause to be complete. Request blood pressure, a full lipid panel including ApoB if available, and fasting glucose. These are your starting point on a trajectory, not a one-time verdict.

2. Set up periodic rechecking every 12 to 18 months through the transition. The shifts are gradual and silent, which means a single measurement is insufficient. You are tracking a trajectory across several years, and the trend matters as much as any individual value.

3. Ask your clinician to document your perimenopausal status in your cardiovascular risk assessment. Many standard risk calculators treat age as a proxy for menopausal status, which underestimates risk in women who are transitioning earlier or faster than the average. Your menopausal history is a cardiovascular variable.

4. If you are experiencing irregular cycles combined with any of the following, severe vasomotor symptoms, significant sleep disruption, or notable changes in your weight distribution toward the abdomen, treat these as reasons to check cardiovascular numbers sooner rather than later. The symptom burden may be a marker of the vascular stress, not just an inconvenience.

5. Pair measurement with the perimenopause heart plan, which translates the numbers into specific interventions matched to what the transition is doing to the body.

The cardiovascular changes of midlife begin in perimenopause, quietly, before the final period. Catching them there, through measurement rather than feel, is where a woman’s prevention is most effective, and it is the reason this transition deserves clinical attention before menopause makes the changes impossible to miss.